Vetter Announces Oliver Albrecht Has Been Appointed Managing Director

Vetter Announces Oliver Albrecht Has Been Appointed Managing Director

 

Role with company commenced on April 1, 2015

Ravensburg, Germany, April 8, 2015 / B3C newswire / -- Vetter, a leading contract development and manufacturing organization that specializes in aseptic manufacturing, today announced that the company's Advisory Board unanimously appointed Oliver Albrecht as a new Managing Director effective April 1, 2015. Albrecht replaces Max Horn as a Vetter Managing Director who left the company in June 2014.

Oliver Albrecht has more than 20 years of experience managing international, medium-sized listed companies both as a Managing Director and as Chief Financial Officer in a wide variety of industries including banking, automotive, and mechanical engineering. In recent years, Oliver held the position as Chief Financial Officer for SHW AG headquartered in Aalen, Germany and acted also as an independent consultant for mid-sized companies.

A seasoned finance and operations executive, Oliver's previous positions include senior posts at companies including Chief Financial Officer for centrotherm photovoltaics AG and as a Director in the Financial and Banking Sector. He holds a diploma in Business from the University of Mannheim, Germany.

"We undertook a rigorous selection process to identify the right person to help lead our company forward," said Udo J. Vetter, Chairman of the company's Advisory Board and member of the owner family. "Oliver's vast experience in a variety of industries, combined with his deep knowledge of achieving operational and financial excellence will be a tremendous asset to Vetter."

In his new role as Managing Director, Albrecht will be responsible for two of the eight company divisions, the first of which is comprised of Finance, Controlling and IT. The second division includes Corporate Development, Legal and Corporate Compliance.

Peter Soelkner and Thomas Otto, Vetter's two Managing Directors added, "we are happy to have this Managing Director position filled with someone having the background that Oliver Albrecht offers. We are pleased to assist our new colleague in any way possible to make his start at Vetter both promising and productive. We wish him success in his new position."

 Oliver Albrecht

Caption: Oliver Albrecht, new Managing Director at Vetter
For high resolution please click the image.


About Vetter
Vetter is a premier contract development and manufacturing organization (CDMO) and a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with facilities in Germany and the United States, the company provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of parenteral drugs. The CDMO's extensive experience covers a broad range of complex compounds, including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company offers a foundation of experience spanning more than 35 years, including dozens of product approvals for novel bio/ pharmaceutical compounds. Since 2014, Vetter operates a representative office in Singapore, increasing the presence of the company and the awareness of its service portfolio in the Asian healthcare market.


Contact

Vetter Pharma International GmbH
Oskar Gold
Senior Vice President Key Account Management,
Marketing / Corporate Communications
Eywiesenstrasse 5
88212 Ravensburg
Phone: +49 (0)751-3700-3023
E-mail: [email protected]

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.